Clinical trials: Polyethylene Glycols
Healthy
Safety, Tolerance, and Pharmacokinetics of Single Rising Oral Doses of BILB 1941 ZW Solution in Healthy Male Subjects, Followed With Bioavailability Comparison of BILB 1941 ZW Tablet and Solution Formulation Administered With or Without Food
The objective of the current study was to investigate the safety, tolerability, and pharmacokinetics of BILB 1941 ZW following the administration of single rising doses from 5 mg to 300 mg.
- Trial name
- NCT02256787
- Testing
- BILB 1941 ZW - single rising dose part, BILB 1941 ZW - solution, BILB 1941 ZW - tablet
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Anemia
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia
This observational study will evaluate the use in clinical practice and efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in stage III-IV chronic kidney disease patients not on dialysis receiving Mircera for the…
- Trial name
- NCT01695746
- Testing
- C.E.R.A.
- Where
- 6 sites in India
- Volunteers
- 108 people
- Sponsor
- Hoffmann-La Roche
Bowel Cleansing Prior to Clinical Procedures
A Study to Investigate Bowel Cleansing With PLENVU® Compared to Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Preparation for Colonoscopy
The purpose of the study is to assess the efficacy, safety and tolerability of PLENVU® by measuring its bowel cleansing success rate compared to sodium picosulfate in paediatric participants aged less than 18 years who are…
- Trial name
- CLARITY (NCT07218523)
- Testing
- PLENVU®, Sodium picosulfate
- Where
- 46 sites in Belgium, Croatia and 8 more
- Volunteers
- 212 people
- Sponsor
- Norgine
Ametropia
Clinical Evaluation of HPT Treated Rigid Contact Lenses Made From Roflufocon D
This will be an up to six months, subject-masked, contralateral, parallel-group, randomised, daily wear study. All subjects will wear the Test lens in one eye and the Control lens in the other eye.
- Trial name
- NCT02553681
- Testing
- roflufocon D contact lenses, RGP contact lenses made from roflufocon D
- Where
- Germany
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Contamac Ltd
Type 2 Diabetes
A Phase I Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes
Polyethylene Glycol Loxenatide (PEX168) is a new human glucagon-like peptide 1 (GLP-1) analogue that created on the basis of the Exenatide and modified by polyethylene glycol (PEG).
- Trial name
- NCT01965496
- Testing
- PEX168
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
A Phase I Study of 8-week Continuous Treatment With Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes
Polyethylene Glycol Loxenatide (PEX168) is a new human glucagon-like peptide 1 (GLP-1) analogue that created on the basis of the Exenatide and modified by polyethylene glycol (PEG).
- Trial name
- NCT01976858
- Testing
- PEX168
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Anemia
A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic Nephropathy
This single arm, open label study will assess the efficacy, safety and tolerability of methoxy polyethylene glycol-epoetin beta for the treatment of chronic renal anemia in participants with chronic kidney disease (CKD) secondary…
- Trial name
- NCT01191983
- Testing
- Methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 14 sites in India
- Volunteers
- 102 people
- Sponsor
- Hoffmann-La Roche
Anemia
An Observational Study of Hemoglobin Stability in Chronic Kidney Disease Patients on Dialysis Treated With Mircera (Methoxy Polyethylene Glycol-epoetin Beta)
This prospective, multicenter, observational study will evaluate the impact of comorbidities on hemoglobin stability in chronic kidney disease patients on dialysis treated with Mircera (methoxy polyethylene glycol-epoetin beta).
- Trial name
- NCT01974271
- Where
- 76 sites in France
- Volunteers
- 661 people
- Sponsor
- Hoffmann-La Roche
Healthy
Single Rising Oral Doses of BI 207127 NA as Powder in the Bottle in Healthy Male Subjects
The objective of this trial was to investigate the safety, tolerability, pharmacokinetics, and relative bioavailability of BI 207127 NA as powder in the bottle (PIB) and solid oral dosage form (tablets) without and with food.
- Trial name
- NCT02182388
- Testing
- BI 207127 NA powder for solution, BI 207127 NA tablet
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Constipation
Safety and Tolerability of Oral Polyethylene Glycol (PEG 3350) Solution in Participants With Constipation (MK-8114-003)
The purpose of this study is to compare the safety and tolerability of oral ingestion of PEG 3350 solution concentrate to oral ingestion of a placebo solution concentrate, in participants with constipation.
- Trial name
- NCT01885104
- Testing
- Polyethylene Glycol (PEG 3350), Bisacodyl laxative tablets (rescue medication)
- Volunteers
- 65 people
- Sponsor
- Bayer
Healthy
Safety of Total Daily Doses of Polyethylene Glycol (PEG) 400 Administered Orally to Healthy Male Human Subjects
To assess the safety and tolerance of 5 mL to 20 mL PEG 400 in multiple rising doses
- Trial name
- NCT02260076
- Testing
- PEG 400
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Chronic Myelogenous Leukemia
Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)
The primary purpose of this study is to compare the efficacy of polyethylene glycol (PEG; pegylated) interferon alfa-2b (PEG Intron, C98026) versus interferon alfa-2b (Intron® A) in the treatment of participants with newly…
- Trial name
- NCT03547154
- Testing
- Pegylated interferon alfa-2b, Interferon alfa-2b
- Volunteers
- 344 people
- Sponsor
- Merck Sharp & Dohme LLC
Kidney Disease, Chronic
A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)
This randomized, single-blind, proof-of-concept study will investigate the protective effects of early treatment with Mircera in participants with chronic kidney disease on renal disease progression.
- Trial name
- NCT01194154
- Testing
- Methoxy polyethylene glycol-epoetin beta
- Where
- 33 sites in Germany
- Volunteers
- 241 people
- Sponsor
- Hoffmann-La Roche
Chronic Kidney Diseases
An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Chronic Kidney Disease Participants on Dialysis
This observational, multi-center, open-label, prospective study will evaluate the relationship between serum interleukin-6 (IL-6) and C-reactive protein (CRP) levels and methoxy polyethylene glycol-epoetin beta dosage in…
- Trial name
- IMPACT (NCT02238080)
- Testing
- Methoxy Polyethylene Glycol-Epoetin Beta
- Where
- 18 sites in Israel
- Volunteers
- 197 people
- Sponsor
- Hoffmann-La Roche
Anemia
OPTIMA: An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Participants With Chronic Kidney Disease Stages 3 and 4 Not on Dialysis
This prospective observational study evaluated the efficacy and safety of Mircera (methoxy polyethylene glycol-epoetin beta) in chronic kidney disease participants on dialysis with renal anemia.
- Trial name
- OPTIMA (NCT01902628)
- Where
- 24 sites in Greece
- Volunteers
- 437 people
- Sponsor
- Hoffmann-La Roche
Anaemia Associated With Chronic Kidney Disease
A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient
This is an open-label, randomised, multicenter, Mircera-controlled, parallel-group, Phase III study to determine whether subcutaneous administered efepoetin alfa is as effective and well tolerated as subcutaneous Mircera for…
- Trial name
- NCT04155125
- Testing
- efepoetin alfa, Mircera
- Where
- 55 sites in Australia, Indonesia and 5 more
- Volunteers
- 391 people
- Sponsor
- PT Kalbe Genexine Biologics
Myoma
Safety and Efficacy Study of a Hydrogel, Applied Following Removal of Myomas During Gynecologic Surgery, Administered for the Prevention/Reduction of Postoperative Adhesion Formation
The purpose of this study was to determine whether the adhesion prevention gel was safe to use, and was effective for the prevention/reduction of adhesion formation that typically occurs following gynecological surgery to remove…
- Trial name
- NCT00562471
- Testing
- Adhibit Adhesion Prevention Gel, Standard of Care Comparator
- Where
- 6 sites in Canada, Germany and 1 more
- Volunteers
- 76 people
- Sponsor
- Angiotech Pharmaceuticals
Constipation
Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216)
Randomized, placebo-controlled, double blind study. 203 subjects entered the study to compare the effect on occasional constipation of polyethylene glycol 3350 to placebo. Subjects took one of study treatments up to 7 days.
- Trial name
- NCT00770432
- Testing
- Polyethylene glycol 3350
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Bayer
Anemia
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Chronic Kidney Disease Patients on Dialysis With Renal Anemia
This observational study will evaluate the use in clinical practice and efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in chronic kidney disease patients on dialysis receiving Mircera for the treatment of chronic…
- Trial name
- NCT01677767
- Where
- 7 sites in India
- Volunteers
- 127 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes Mellitus
Polyethylene Glycol Loxenatide Pharmacokinetics Study in Subjects With Normal and Insufficiency Renal Function
To compare and analysis pharmacokinetics of PEX 168 in patients with renal insufficiency or normal renal function who were administrated subcutaneously single dose PEX168.To evaluate dose adjustment of PEX168 administered in…
- Trial name
- NCT02467790
- Testing
- PEX168
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.